Short Interest in DarioHealth Corp. (NASDAQ:DRIO) Decreases By 26.4%

DarioHealth Corp. (NASDAQ:DRIO) was the recipient of a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling 173,300 shares, a decline of 26.4% from the September 30th total of 235,500 shares. Based on an average trading volume of 64,500 shares, the short-interest ratio is presently 2.7 days. Currently, 3.3% of the shares of the company are sold short. Currently, 3.3% of the shares of the company are sold short. Based on an average trading volume of 64,500 shares, the short-interest ratio is presently 2.7 days.

DarioHealth Stock Down 1.7%

Shares of DRIO opened at $13.50 on Wednesday. The company has a market capitalization of $30.71 million, a P/E ratio of -1.02 and a beta of 1.31. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.30 and a quick ratio of 2.83. DarioHealth has a one year low of $5.93 and a one year high of $31.00. The business’s 50 day simple moving average is $12.21 and its 200-day simple moving average is $12.88.

Institutional Inflows and Outflows

An institutional investor recently raised its position in DarioHealth stock. XTX Topco Ltd lifted its holdings in shares of DarioHealth Corp. (NASDAQ:DRIO) by 229.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,511 shares of the company’s stock after buying an additional 43,513 shares during the quarter. XTX Topco Ltd owned about 0.14% of DarioHealth worth $42,000 at the end of the most recent quarter. Institutional investors and hedge funds own 33.39% of the company’s stock.

Analyst Upgrades and Downgrades

DRIO has been the topic of a number of recent research reports. Wall Street Zen raised DarioHealth to a “sell” rating in a report on Saturday, October 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of DarioHealth in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $40.00.

DarioHealth Company Profile

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.